Biomarker for predicting sensitivity of melanoma patient to immunotherapy, application and device

A biomarker and immunotherapy technology, applied in the field of biomarkers for predicting the sensitivity of melanoma patients to immunotherapy, can solve the problems of long work cycle, high sequencing cost, and high technical platform requirements

Pending Publication Date: 2022-04-29
SHANGHAI ORIGIMED CO LTD +2
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, TMB detection has high requirements on the tec...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for predicting sensitivity of melanoma patient to immunotherapy, application and device
  • Biomarker for predicting sensitivity of melanoma patient to immunotherapy, application and device
  • Biomarker for predicting sensitivity of melanoma patient to immunotherapy, application and device

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] 1. Data Acquisition

[0075] The data of 100 patients with advanced (Phase IV) skin melanoma (Skin Cutaneous Melanoma, SKCM) treated with immune checkpoint inhibitors (ipilimumab) were obtained from the DFCI (Dana-Farber Cancer Institute) database, including Gene mutation data, treatment plan data and overall survival (Overall Survival, OS) data are shown in Table 2.

[0076] Samples with somatic non-synonymous mutations in the HERC1 gene (including at least one of missense mutations, in-frame insertion mutations, in-frame deletion mutations, nonsense mutations, frameshift mutations, and splice site mutations) were classified as HERC1 =MUT group, wherein the number of samples is 9, and the specific mutation sites are p.G3682E, p.S2422F, p.T4807I, p.V374A, p.S463F, p.H1447Y, p.P216L, p.T22A or p. L1148F; The samples without any somatic non-synonymous mutations in the HERC1 gene or only mutations in the non-coding region of the HERC1 gene were classified as the HERC1=WT ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a biomarker for predicting sensitivity of a melanoma patient to immunotherapy, application and a device. The biomarker for predicting the sensitivity of the melanoma patient to the immunotherapy comprises a mutant HERC1 gene, the mutation of the gene has significant correlation with a TMB value, the gene can be used as a new biomarker for predicting the sensitivity of the melanoma patient to the immunotherapy, people beneficial to the immunotherapy can be rapidly screened, the accuracy rate is high, the detection cost is saved, and the method is suitable for popularization and application. The population coverage of the melanoma patients which can benefit from immunotherapy is expanded and recognized, and the method has important significance on treatment of the melanoma patients.

Description

technical field [0001] The present invention relates to the field of molecular biology, in particular to a biomarker, application and device for predicting sensitivity of melanoma patients to immunotherapy. Background technique [0002] The classic treatment methods for advanced melanoma are targeted therapy, chemotherapy and / or radiotherapy. However, with the development of the treatment process, cancer cells will eventually adapt and gradually develop corresponding drug resistance. Immune checkpoint inhibitors (Immune Checkpoint Inhibitors, ICIs) have brought great changes in the treatment of advanced melanoma, however, only some melanoma patients can benefit from this treatment, so there is an urgent need for effective biomarkers to predict clinical Beneficiaries. At present, common clinical immunotherapy efficacy prediction biomarkers include TMB and PD-L1, which have shown certain predictive efficacy, but there are still many limitations. [0003] PD-L1 is the most w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6886G01N33/574G16B20/50
CPCC12Q1/6886G01N33/5743G01N33/57484G16B20/50G01N2333/70532G01N2333/70521G01N2333/9108G01N2333/9015
Inventor 张玉满张昭
Owner SHANGHAI ORIGIMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap